GHP Healthcare & Pharmaceutical Awards 2018

32 GHP / 2018 Healthcare & Pharmaceutical Awards , HP180037 Best Patient Monitoring Technology Manufacturer 2018 Masimo is a global medical technology company that develops and manufactures noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. As we have recently recognised the firm in this year’s Healthcare & Pharmaceutical Awards, we share an insight into the work it undertakes and the unique solutions it provides. Company: Masimo Contact: Evan Lamb Address: 52 Discovery, Irvine, CA 92618, USA Phone: +1 949 297 7000 Website: Established in 1989, Masimo is the result of Founder Joe Kiani’s belief that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry, was shown in a study comparing three pulse oximetry technologies to demonstrate the highest sensitivity and specificity in identifying desaturation events during conditions of motion and low perfusion. 1 Another of the firm’s solutions is rainbow ® , which was introduced in 2005 and allows additional parameters to be noninvasively and continuously monitored. Advanced signal processing algorithms and unique adaptive filters work together to isolate, identify, and quantify various types of haemoglobin. Today, thanks to these innovative solutions, the firm’s work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life. Now publicly traded and employing over 4,600 people worldwide, with annual revenues of approximately $800 million (USD), Masimo has achieved incredible success. Licensing agreements allow the firm technology to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Medical, Spacelabs, and Zoll. Throughout its journey, Masimo’s mission—to improve patient outcomes and reduce the cost of care—has remained its core focus. Over the years the firm’s product offering has grown and now the Masimo SET ® and rainbow ® technologies, collectively known as rainbow SET™, fuel medical monitoring devices such as Root ® , Radical-7 ®, Radius-7 ® , Rad-97™, and Rad-67™ as well as a multitude of sensors, including the RD collection. These highly versatile monitors are configurable for use in a variety of high- and low-acuity hospital settings, from ICUs and surgical suites to post-operative floors, as well as in long-term care facilities and in the case of Rad-97, for home use. Complementing devices that primarily monitor continuously, Masimo’s spot-check devices such as Rad-67, Pronto ® , MightySat™ Rx, and iSpO ® Rx allow physician offices, EMS responders, and others to measure oxygen saturation and other valuable measurements. MightySat is also available for personal use for general health and wellness applications. Joining the expanding set of monitoring possibilities are redefined and extended connectivity and automation solutions. Among these is Masimo Iris Gateway™, which gathers medical data from devices throughout the hospital, including ADT systems, and converts and transfers them to a central repository, the EMR, thus automating clinician access to a more complete picture of each patient. To those abilities, Masimo Patient SafetyNet™* with Replica™ adds hospital- wide monitoring and two-way remote clinician notification from a central server, customisable view stations, and mobile devices. The wearable Masimo Radius-7 allows for the tether-less monitoring of mobile patients, communicating alarms wirelessly back to Root and Patient SafetyNet. Ultimately, for more than 28 years Masimo’s innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimise clinical decision-making. Moving forward, the firm will continue to enhance this and expand its reach to support an even wider array of clients and build upon its already impressive success. 1 Shah N et al. 2012 Aug; 24(5):385-91. *The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium. 3 Rad-97 models